Clinical and Laboratory Data of Neutropenic Patients With and Without Infections
. | No Infections (n = 51) . | Infections (n = 15) . | TwoSided P Value . |
---|---|---|---|
Male:female | 20:31 | 3:12 | NS* |
Age | 53 (range: 18-88) | 61 (31-82) | NS |
ANC (cells/μL)-151 | 1,170 ± 320-152 | 860 ± 477 | .03 |
Range (cells/μL) | 600-1,500 | 50-1,500 | |
Plasma sFcγRIII (AU) | 109 ± 66 | 49 ± 26 | <.0001 |
Range (AU) | 23-315 | 11-95 | |
Bone marrow data | |||
Not available | 19 (37%) | 4 (25%) | |
Normal marrow | 25 (49%) | 5 (31%) | |
Decreased myelopoiesis | 2 (4%) | 1 (6%) | |
Increased myelopoiesis | 2 (4%) | 2 (13%) | |
Possible dysplasia | 2 (4%) | 2 (13%) | |
Lymphocytosis | 1 (2%) | 1 (6%) | |
FcγR genotype-153 | |||
FcγRIIA-131R | 0.59 | 0.61 | |
FcγRIIA-131H | 0.41 | 0.39 | NS |
FcγRIIIB-NA1 | 0.29 | 0.32 | |
FcγRIIIB-NA2 | 0.71 | 0.68 | NS |
. | No Infections (n = 51) . | Infections (n = 15) . | TwoSided P Value . |
---|---|---|---|
Male:female | 20:31 | 3:12 | NS* |
Age | 53 (range: 18-88) | 61 (31-82) | NS |
ANC (cells/μL)-151 | 1,170 ± 320-152 | 860 ± 477 | .03 |
Range (cells/μL) | 600-1,500 | 50-1,500 | |
Plasma sFcγRIII (AU) | 109 ± 66 | 49 ± 26 | <.0001 |
Range (AU) | 23-315 | 11-95 | |
Bone marrow data | |||
Not available | 19 (37%) | 4 (25%) | |
Normal marrow | 25 (49%) | 5 (31%) | |
Decreased myelopoiesis | 2 (4%) | 1 (6%) | |
Increased myelopoiesis | 2 (4%) | 2 (13%) | |
Possible dysplasia | 2 (4%) | 2 (13%) | |
Lymphocytosis | 1 (2%) | 1 (6%) | |
FcγR genotype-153 | |||
FcγRIIA-131R | 0.59 | 0.61 | |
FcγRIIA-131H | 0.41 | 0.39 | NS |
FcγRIIIB-NA1 | 0.29 | 0.32 | |
FcγRIIIB-NA2 | 0.71 | 0.68 | NS |